From our list 18 new health tech startups in Europe worth knowing (2026)
Constellate Proteomics develops RAYmAb, a platform that runs four antibody quality checks (titre, glycosylation, aggregation and charge variants) on a small, untreated sample in minutes, where current methods take weeks of specialised work; it is aimed at biotech, pharma and contract manufacturing teams that develop antibody drugs. It was spun out of TU Delft in February 2026 by Carlos de Lannoy (CEO), Arian Khoshchin and Dennis de Beeld. IO+ reported on 21 October 2026 that it raised a 150,000 euro pre-seed round in convertible financing from Tech Scout Venture Fund and Imec.istart. Website: constellate.pro. Source: IO+. Also in our list: New startups in the Netherlands (2026).
Questions about Constellate Proteomics
What does Constellate Proteomics do?
Constellate Proteomics: antibody quality checks in minutes instead of weeks.
Where is Constellate Proteomics based?
Constellate Proteomics is based in Delft, Netherlands.
Where can I read more about Constellate Proteomics?
Constellate Proteomics is in our list 18 new health tech startups in Europe worth knowing (2026): https://meetnewbrands.com/articles/new-health-tech-startups-in-europe-2026